Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.

Paolo Giorgi Rossi, Alessandro Ricciardi, Catherine Cohet, Fabio Palazzo, Giacomo Furnari, Sabrina Valle, Nathalie Largeron, Antonio Federici

Research output: Contribution to journalArticle

Abstract

BACKGROUND: We estimated the number of women undergoing cervical cancer screening annually in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of abnormalities. METHODS: The annual number of screened women was estimated from National Health Interview data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and treatment costs were estimated using a typical disease management approach based on national guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs were obtained from Italian National Health Service and Hospital Information System of the Lazio Region. RESULTS: An estimated 6.4 million women aged 25-69 years undergo screening annually in Italy (1.2 million and 5.2 million through organized and opportunistic screening programs, respectively). Approximately 2.4% of tests have positive findings. There are approximately 21,000 cases of CIN1 and 7,000-17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to 158.5 million euro for screening and 22.9 million euro for the management of cervical abnormalities. CONCLUSION: Although some cervical abnormalities might have been underestimated, the total annual cost of cervical cancer prevention in Italy is approximately 181.5 million euro, of which 87% is attributable to screening.

Original languageEnglish
Pages (from-to)71
Number of pages1
JournalBMC Public Health
Volume9
DOIs
Publication statusPublished - 2009

Fingerprint

Uterine Cervical Dysplasia
Early Detection of Cancer
Uterine Cervical Neoplasms
Italy
Epidemiology
Health Care Costs
Costs and Cost Analysis
Hospital Information Systems
Health Information Systems
Papanicolaou Test
National Health Programs
Disease Management
Registries
Neoplasms
Guidelines
Interviews
Incidence
Health

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. / Giorgi Rossi, Paolo; Ricciardi, Alessandro; Cohet, Catherine; Palazzo, Fabio; Furnari, Giacomo; Valle, Sabrina; Largeron, Nathalie; Federici, Antonio.

In: BMC Public Health, Vol. 9, 2009, p. 71.

Research output: Contribution to journalArticle

Giorgi Rossi, P, Ricciardi, A, Cohet, C, Palazzo, F, Furnari, G, Valle, S, Largeron, N & Federici, A 2009, 'Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.', BMC Public Health, vol. 9, pp. 71. https://doi.org/10.1186/1471-2458-9-71
Giorgi Rossi, Paolo ; Ricciardi, Alessandro ; Cohet, Catherine ; Palazzo, Fabio ; Furnari, Giacomo ; Valle, Sabrina ; Largeron, Nathalie ; Federici, Antonio. / Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy. In: BMC Public Health. 2009 ; Vol. 9. pp. 71.
@article{becea68d2c5c4bf2b2fc27b55fd321f8,
title = "Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.",
abstract = "BACKGROUND: We estimated the number of women undergoing cervical cancer screening annually in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of abnormalities. METHODS: The annual number of screened women was estimated from National Health Interview data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and treatment costs were estimated using a typical disease management approach based on national guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs were obtained from Italian National Health Service and Hospital Information System of the Lazio Region. RESULTS: An estimated 6.4 million women aged 25-69 years undergo screening annually in Italy (1.2 million and 5.2 million through organized and opportunistic screening programs, respectively). Approximately 2.4{\%} of tests have positive findings. There are approximately 21,000 cases of CIN1 and 7,000-17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to 158.5 million euro for screening and 22.9 million euro for the management of cervical abnormalities. CONCLUSION: Although some cervical abnormalities might have been underestimated, the total annual cost of cervical cancer prevention in Italy is approximately 181.5 million euro, of which 87{\%} is attributable to screening.",
author = "{Giorgi Rossi}, Paolo and Alessandro Ricciardi and Catherine Cohet and Fabio Palazzo and Giacomo Furnari and Sabrina Valle and Nathalie Largeron and Antonio Federici",
year = "2009",
doi = "10.1186/1471-2458-9-71",
language = "English",
volume = "9",
pages = "71",
journal = "BMC Public Health",
issn = "1471-2458",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy.

AU - Giorgi Rossi, Paolo

AU - Ricciardi, Alessandro

AU - Cohet, Catherine

AU - Palazzo, Fabio

AU - Furnari, Giacomo

AU - Valle, Sabrina

AU - Largeron, Nathalie

AU - Federici, Antonio

PY - 2009

Y1 - 2009

N2 - BACKGROUND: We estimated the number of women undergoing cervical cancer screening annually in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of abnormalities. METHODS: The annual number of screened women was estimated from National Health Interview data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and treatment costs were estimated using a typical disease management approach based on national guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs were obtained from Italian National Health Service and Hospital Information System of the Lazio Region. RESULTS: An estimated 6.4 million women aged 25-69 years undergo screening annually in Italy (1.2 million and 5.2 million through organized and opportunistic screening programs, respectively). Approximately 2.4% of tests have positive findings. There are approximately 21,000 cases of CIN1 and 7,000-17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to 158.5 million euro for screening and 22.9 million euro for the management of cervical abnormalities. CONCLUSION: Although some cervical abnormalities might have been underestimated, the total annual cost of cervical cancer prevention in Italy is approximately 181.5 million euro, of which 87% is attributable to screening.

AB - BACKGROUND: We estimated the number of women undergoing cervical cancer screening annually in Italy, the rates of cervical abnormalities detected, and the costs of screening and management of abnormalities. METHODS: The annual number of screened women was estimated from National Health Interview data. Data from the Italian Group for Cervical Cancer Screening were used to estimate the number of positive, negative and unsatisfactory Pap smears. The incidence of CIN (cervical intra-epithelial neoplasia) was estimated from the Emilia Romagna Cancer Registry. Patterns of follow-up and treatment costs were estimated using a typical disease management approach based on national guidelines and data from the Italian Group for Cervical Cancer Screening. Treatment unit costs were obtained from Italian National Health Service and Hospital Information System of the Lazio Region. RESULTS: An estimated 6.4 million women aged 25-69 years undergo screening annually in Italy (1.2 million and 5.2 million through organized and opportunistic screening programs, respectively). Approximately 2.4% of tests have positive findings. There are approximately 21,000 cases of CIN1 and 7,000-17,000 cases of CIN2/3. Estimated costs to the healthcare service amount to 158.5 million euro for screening and 22.9 million euro for the management of cervical abnormalities. CONCLUSION: Although some cervical abnormalities might have been underestimated, the total annual cost of cervical cancer prevention in Italy is approximately 181.5 million euro, of which 87% is attributable to screening.

UR - http://www.scopus.com/inward/record.url?scp=64949089223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949089223&partnerID=8YFLogxK

U2 - 10.1186/1471-2458-9-71

DO - 10.1186/1471-2458-9-71

M3 - Article

C2 - 19243586

AN - SCOPUS:61849084587

VL - 9

SP - 71

JO - BMC Public Health

JF - BMC Public Health

SN - 1471-2458

ER -